Cordis puts the nitric oxide (NO) in restenosis:
This article was originally published in Clinica
Cordis and NitroMed are collaborating to develop a stent that gives off nitric oxide in an attempt to prevent restenosis. Restenosis, the re-narrowing of arteries after angioplasty, is caused by a combination of elastic recoil and uncontrolled division of cells in response to wounding. Nitric oxide can suppress the cell proliferation. Cordis and NitroMed will develop a stent coated with a nitric oxide donor for use in a variety of cardiovascular applications.
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.